Silvia Sanchez-Ramon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2196146/publications.pdf

Version: 2024-02-01

174	8,921	87888	49909
papers	citations	38 h-index	87 g-index

190	190	190	14798
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. European Journal of Health Economics, 2022, 23, 551-558.	2.8	10
2	To the Editor: â€œComplete Resolution of Multiple Warts after a First Dose of the Receptor Interleukin-5 Inhibitorâ€• Journal of Clinical Immunology, 2022, , 1.	3.8	0
3	The PID Life Index: an interactive tool to measure the status of the PID healthcare environment in any given country. Orphanet Journal of Rare Diseases, 2022, 17, 11.	2.7	5
4	Intravenous Immunoglobulins Promote an Expansion of Monocytic Myeloid-Derived Suppressor Cells (MDSC) in CVID Patients. Journal of Clinical Immunology, 2022, 42, 1093-1105.	3.8	2
5	Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies. Journal of Translational Autoimmunity, 2022, 5, 100160.	4.0	5
6	Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. Journal of Allergy and Clinical Immunology, 2021, 147, 520-531.	2.9	278
7	Immunodeficiency and thymoma in Good syndrome: Two sides of the same coin. Immunology Letters, 2021, 231, 11-17.	2.5	21
8	Complete Spontaneous Regression of Lung Metastases after Resection of CIC-Rearranged Sarcoma: A Case Report. Case Reports in Oncology, 2021, 14, 152-159.	0.7	1
9	Functional NK surrogate biomarkers for inflammatory recurrent pregnancy loss and recurrent implantation failure. American Journal of Reproductive Immunology, 2021, 86, e13426.	1.2	7
10	Serological Tests in the Detection of SARS-CoV-2 Antibodies. Diagnostics, 2021, 11, 678.	2.6	9
11	Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. Journal of Allergy and Clinical Immunology, 2021, 148, 1332-1341.e5.	2.9	75
12	Next Generation Sequencing for Detecting Somatic FAS Mutations in Patients With Autoimmune Lymphoproliferative Syndrome. Frontiers in Immunology, 2021, 12, 656356.	4.8	12
13	Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment. Frontiers in Immunology, 2021, 12, 675735.	4.8	10
14	Editorial: Trained Immunity-Based Vaccines. Frontiers in Immunology, 2021, 12, 716296.	4.8	4
15	Variable immunodeficiency score upfront analytical link (VISUAL), a proposal for combined prognostic score at diagnosis of common variable immunodeficiency. Scientific Reports, 2021, 11, 12211.	3.3	2
16	Bâ€cell haematological malignancies and SARSâ€CoVâ€2 infection: Could immunological interventions influence the outcome?. EJHaem, 2021, 2, 503-507.	1.0	5
17	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	11.9	357
18	Editorial: The Crossroads Between Immunological Disorders and Neuropsychiatric Diseases. A Case for Schizophrenia. Frontiers in Cellular Neuroscience, 2021, 15, 733997.	3.7	2

#	Article	IF	Citations
19	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Science Immunology, 2021, 6, .	11.9	267
20	On the relevance of immunodeficiency evaluation in haematological cancer. Hematological Oncology, 2021, 39, 721-723.	1.7	3
21	Clinical and Immunological Features of Human BCL10 Deficiency. Frontiers in Immunology, 2021, 12, 786572.	4.8	13
22	The PID Principles of Care: Where Are We Now? A Global Status Report Based on the PID Life Index. Frontiers in Immunology, 2021, 12, 780140.	4.8	18
23	Vacunas antiinfecciosas de mucosas en la profilaxis de infecciones recurrentes: mÃ¡s allÃ¡ de las vacunas convencionales. ReumatologÃa ClÃnica, 2020, 16, 49-55.	0.5	6
24	Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies. Clinical Immunology, 2020, 210, 108307.	3.2	13
25	Trained Immunity Based-Vaccines as a Prophylactic Strategy in Common Variable Immunodeficiency. A Proof of Concept Study. Biomedicines, 2020, 8, 203.	3.2	17
26	A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants. Expert Review of Clinical Immunology, 2020, 16, 911-921.	3.0	13
27	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,749
28	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,983
29	Serum Free Immunoglobulins Light Chains: A Common Feature of Common Variable Immunodeficiency?. Frontiers in Immunology, 2020, 11, 2004.	4.8	6
30	1767P Hypercoagulable state, CD4+ T-lymphocytopenia, dysregulated cytotoxicity and monocyte upregulation in COVID-19 positive cancer patients presenting with severe pneumonia. Annals of Oncology, 2020, 31, S1026-S1027.	1.2	0
31	Self and the Brain. The Immune Metaphor. Frontiers in Psychiatry, 2020, 11, 540676.	2.6	2
32	Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 438-443.	0.3	0
33	Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 438-443.	0.5	0
34	Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3342-3347.	3.8	7
35	Typhim vi immunization assists to discriminate primary antibody responses in hematological malignancies. MethodsX, 2020, 7, 100936.	1.6	0
36	Human BCL10 Deficiency due to Homozygosity for a Rare Allele. Journal of Clinical Immunology, 2020, 40, 388-398.	3.8	17

#	Article	IF	Citations
37	Variable immunodeficiency study: Evaluation of two European cohorts within a variety of clinical phenotypes. Immunology Letters, 2020, 223, 78-88.	2.5	5
38	A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections. Frontiers in Immunology, 2020, 11, 612269.	4.8	18
39	Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach. Frontiers in Immunology, 2020, 11, 611566.	4.8	8
40	Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma. Hematology/ Oncology and Stem Cell Therapy, 2020, , .	0.9	15
41	Measurement of Typhim Vi IgG as a Diagnostic Tool to Determine Anti-polysaccharide Antibody Production Deficiency in Children. Frontiers in Immunology, 2019, 10, 654.	4.8	14
42	Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management. Frontiers in Immunology, 2019, 10, 586.	4.8	40
43	Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges. Frontiers in Cellular Neuroscience, 2019, 13, 107.	3.7	18
44	Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. European Journal of Haematology, 2019, 102, 447-456.	2.2	60
45	Double-strand break repair through homologous recombination in autosomal-recessive BCL10 deficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 1931-1934.e1.	2.9	2
46	Vaccine Response to a Neo Polyssacharide Antigen Typhim Vi on the Identification of Secondary Immunodeficiencies in Hematological Malignancy. Blood, 2019, 134, 3600-3600.	1.4	0
47	Recomendaciones para el estudio genÃ©tico e inmunolÃ³gico en la disfunciÃ³n reproductiva. Medicina ClÃnica, 2018, 151, 161.e1-161.e12.	0.6	0
48	Blood monocytes sample <scp>M</scp>elanA/<scp>MART</scp>1 antigen for longâ€lasting crossâ€presentation to <scp>CD</scp>8⁺<scp>T</scp> cells after differentiation into dendritic cells. International Journal of Cancer, 2018, 142, 133-144.	5.1	14
49	Human dendritic cells activated with MV130 induce Th1, Th17 and ILâ€10 responses via RIPK2 and MyD88 signalling pathways. European Journal of Immunology, 2018, 48, 180-193.	2.9	48
50	Clinical and Immunological Response to Sublingual Vaccination for the Prevention of Recurrent Urinary Tract Infections in Kidney Transplant Patients. Transplantation, 2018, 102, S320.	1.0	1
51	Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management. Respiratory Research, 2018, 19, 219.	3.6	30
52	Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Frontiers in Immunology, 2018, 9, 2936.	4.8	187
53	Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4. Clinical and Experimental Immunology, 2018, 194, 166-179.	2.6	53
54	Recommendations regarding the genetic and immunological study of reproductive dysfunction. Medicina ClÃnica (English Edition), 2018, 151, 161.e1-161.e12.	0.2	0

#	Article	IF	Citations
55	Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity. Journal of Immunological Methods, 2018, 459, 1-10.	1.4	17
56	Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481878361.	3.2	14
57	Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-Î²-Treated Relapsingâ€“Remitting-Multiple Sclerosis Patients. Frontiers in Immunology, 2018, 9, 1240.	4.8	17
58	Monocyte-Derived Dendritic Cells Differentiated in the Presence of Lenalidomide Display a Semi-Mature Phenotype, Enhanced Phagocytic Capacity, and Th1 Polarization Capability. Frontiers in Immunology, 2018, 9, 1328.	4.8	12
59	IVIg Promote Cross-Tolerance against Inflammatory Stimuli In Vitro and In Vivo. Journal of Immunology, 2018, 201, 41-52.	0.8	16
60	THU0034â€…Salmonella typhi vi igg as a marker of immunosuppression in rheumatic disease. , 2018, , .		0
61	Close Encounters of the First Kind: Innate Sensors and Multiple Sclerosis. Molecular Neurobiology, 2017, 54, 101-114.	4.0	7
62	Nuevas posibilidades de tratamiento con inmunoglobulinas subcutÃ¡neas. Medicina ClÃnica, 2017, 148, 86-90.	0.6	0
63	Multimarker risk stratification approach at multiple sclerosis onset. Clinical Immunology, 2017, 181, 43-50.	3.2	9
64	New choices for treatment with subcutaneous immunoglobulins. Medicina ClÃnica (English Edition), 2017, 148, 86-90.	0.2	0
65	Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clinical and Experimental Immunology, 2017, 190, 226-234.	2.6	25
66	dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. International Journal of Molecular Sciences, 2017, 18, 1328.	4.1	44
67	Activation of Blood CD3+CD56+CD8+ T Cells during Pregnancy and Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 196.	4.8	17
68	The Thymus/Neocortex Hypothesis of the Brain: A Cell Basis for Recognition and Instruction of Self. Frontiers in Cellular Neuroscience, 2017, 11, 340.	3.7	3
69	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43
70	Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis. Current Medicinal Chemistry, 2017, 24, 176-192.	2.4	18
71	Thinking Outside the Brain: Immunorregulation in Multiple Sclerosis. Current Immunology Reviews, 2017, 12, 98-111.	1.2	1
72	Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy. Frontiers in Immunology, 2016, 7, 317.	4.8	30

#	Article	IF	Citations
73	Through the Immune Looking Glass: A Model for Brain Memory Strategies. Frontiers in Cellular Neuroscience, 2016, 10, 17.	3.7	3
74	AB1007â€...Recurrent Infection after Biologicals in Autoimmune Disease: Preliminary Results with Mucosal Vaccines Recurrent Infection after Biologicals in Autoimmune Disease: Preliminary Results with Mucosal Vaccines. Annals of the Rheumatic Diseases, 2016, 75, 1246.1-1246.	0.9	0
75	Sa1955 Comparison of Four Assay Kits for Measuring Infliximab Trough Levels and Antibodies to Infliximab in Patients With Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S415.	1.3	3
76	The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?. Immunotherapy, 2016, 8, 601-612.	2.0	8
77	Gain-of-function mutation in PIK3R1 in a patient with a narrow clinical phenotype of respiratory infections. Clinical Immunology, 2016, 173, 117-120.	3.2	17
78	Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti -polysaccharide antibody production deficiency in patients with primary immunodeficiency. Clinical Immunology, 2016, 169, 80-84.	3.2	34
79	Whole-exome sequencing to analyze population structure, parental inbreeding, and familial linkage. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6713-6718.	7.1	53
80	Actin polymerisation after FCÎ³R stimulation of human fibroblasts is BCL10 independent. Clinical Immunology, 2016, 163, 120-122.	3.2	4
81	The absence of evidence is not the evidence of absence. Human Reproduction, 2016, 31, 217-218.	0.9	2
82	New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice. Current Pharmaceutical Design, 2016, 22, 6283-6293.	1.9	19
83	Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?. Current Pharmaceutical Design, 2016, 22, 6300-6305.	1.9	3
84	Omalizumab for the treatment of atopic dermatitis. Clinical Investigation, 2015, 5, 121-136.	0.0	4
85	Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis. PLoS ONE, 2015, 10, e0128952.	2.5	40
86	Antibodies to Mitotic Apparatus: New Association With Cholestatic Liver Disease. American Journal of Gastroenterology, 2015, 110, 1736-1737.	0.4	4
87	Hurdles in therapy with regulatory T cells. Science Translational Medicine, 2015, 7, 304ps18.	12.4	136
88	Changes in B and T-cell subsets and NMO-IgG/AQP-4 levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica. NeurologÃa (English Edition), 2015, 30, 276-282.	0.4	2
89	Genetic errors of the human caspase recruitment domainâ€“B-cell lymphoma 10â€“mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity. Journal of Allergy and Clinical Immunology, 2015, 136, 1139-1149.	2.9	65
90	Cambios en las Subpoblaciones de Linfocitos B y T en el TÃtulo de Anticuerpos Anti-Acuaporina-4 tras el Tratamiento de un Brote Agudo con Inmunoglobulinas y Rituximab. NeurologÃa, 2015, 30, 276-282.	0.7	4

#	Article	IF	Citations
91	Illusory lower limb levitation and involuntary moving toes following herpes zoster myelitis.. Case Reports in Internal Medicine, 2014, 2, .	0.0	0
92	Primary Immune Deficiencies - Principles of Care. Frontiers in Immunology, 2014, 5, 627.	4.8	70
93	Low DPP4 expression and activity in multiple sclerosis. Clinical Immunology, 2014, 150, 170-183.	3.2	34
94	Intravenous Immunoglobulin Promotes Antitumor Responses by Modulating Macrophage Polarization. Journal of Immunology, 2014, 193, 5181-5189.	0.8	39
95	Experience in <scp>IVI</scp>g Therapy for Selected Women with Recurrent Reproductive Failure and <scp>NK</scp> Cell Expansion. American Journal of Reproductive Immunology, 2014, 71, 458-466.	1.2	47
96	New regulatory CD19+CD25+ B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids. Journal of Neuroimmunology, 2014, 270, 37-44.	2.3	48
97	Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity. Journal of Clinical Investigation, 2014, 124, 5239-5248.	8.2	97
98	Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects. Current Drug Targets, 2014, 15, 1132-1143.	2.1	11
99	Immunological Causes Associated to Foetal Death: An Update. International Journal of Gynecological and Obstetrical Research, 2014, 2, 50-57.	0.1	0
100	Modelos de reconocimiento inmunolÃ³gico: tolerancia e inmunidad en el marco de la evoluciÃ³n del conocimiento cientÃfico. Inmunologia (Barcelona, Spain: 1987), 2013, 32, 139-147.	0.1	0
101	Anti-IL-6R therapy on Graves' ophthalmopathy. Clinical Immunology, 2013, 147, 120-121.	3.2	10
102	Female sex hormones regulate the Th17 immune response to sperm and Candida albicans. Human Reproduction, 2013, 28, 3283-3291.	0.9	28
103	New <scp>D</scp>ecisionâ€<scp>T</scp>ree <scp>M</scp>odel for <scp>D</scp>efining the <scp>R</scp>isk of <scp>R</scp>eproductive <scp>F</scp>ailure. American Journal of Reproductive Immunology, 2013, 70, 59-68.	1.2	19
104	Research update for articles published in <scp>EJCI</scp> in 2011. European Journal of Clinical Investigation, 2013, 43, 1097-1110.	3.4	2
105	Aryl hydrocarbon receptor contributes to the MEK/ERK-dependent maintenance of the immature state of human dendritic cells. Blood, 2013, 121, e108-e117.	1.4	37
106	Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. Journal of Investigational Allergology and Clinical Immunology, 2013, 23, 190-6.	1.3	30
107	Perforin Expression by CD4+ Regulatory T Cells Increases at Multiple Sclerosis Relapse: Sex Differences. International Journal of Molecular Sciences, 2012, 13, 6698-6710.	4.1	15
108	Sex-hormone receptors pattern on regulatory T-cells: clinical implications for multiple sclerosis. Clinical and Experimental Medicine, 2012, 12, 247-255.	3.6	39

#	Article	IF	Citations
109	Omalizumab en el tratamiento de la dermatitis atÃ³pica. Actas Dermo-sifiliogrÃ¡ficas, 2012, 103, 624-628.	0.4	36
110	Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis. PLoS ONE, 2012, 7, e34103.	2.5	44
111	The European internet-based patient and research database for primary immunodeficiencies: update 2011. Clinical and Experimental Immunology, 2012, 167, 479-491.	2.6	91
112	Intravenous Immunoglobulin Treatment Increased Live Birth Rate in a <scp>S</scp>panish Cohort of Women with Recurrent Reproductive Failure and Expanded <scp>CD</scp>56⁺ Cells. American Journal of Reproductive Immunology, 2012, 68, 75-84.	1.2	80
113	Defining risk for recurrent gestational failure by blood natural killer cells subsets. Journal of Reproductive Immunology, 2012, 94, 23.	1.9	0
114	Increased prevalence of undiagnosed celiac disease among women with recurrent pregnancy loss: experience in Spain. Journal of Reproductive Immunology, 2012, 94, 112.	1.9	1
115	TLR-Mediated B Cell Defects and IFN-Î± in Common Variable Immunodeficiency. Journal of Clinical Immunology, 2012, 32, 50-60.	3.8	35
116	The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood, 2011, 117, 88-97.	1.4	299
117	Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clinical and Experimental Immunology, 2011, 164, 100-107.	2.6	57
118	Estradiol-dependent perforin expression by human regulatory T-cells. European Journal of Clinical Investigation, 2011, 41, 357-364.	3.4	42
119	297 Expanded Circulating Regulatory T-Cells in Very Low Birth Weight Neonates: A Mechanism for Tolerance or a Threat for Sepsis?. Pediatric Research, 2010, 68, 153-153.	2.3	0
120	1400 Nosocomial Infection and Cd4+ Lymphocytes in Very Low Birth Weight (VLBW) Infants' Cord Blood. Pediatric Research, 2010, 68, 692-692.	2.3	0
121	Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy. Rheumatology International, 2010, 30, 817-819.	3.0	15
122	Tratamiento del pÃ©nfigo. Piel, 2010, 25, 338-343.	0.0	0
123	IFNÎ²-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: A longitudinal 1-year study. Clinical Immunology, 2010, 134, 148-157.	3.2	22
124	Severe Refractory Hidradenitis Suppurativa in an HIV-Positive Patient Successfully Treated With Infliximab. Archives of Dermatology, 2010, 146, 1343.	1.4	24
125	Clinical response to interferon-Î²-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells. Journal of Neuroimmunology, 2009, 212, 112-120.	2.3	10
126	Association between antiâ€“cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2009, 61, 419-424.	6.7	149

#	Article	IF	Citations
127	NK cell expansion in obstetrical antiphospholipid syndrome: Guilty by association?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 145, 227.	1.1	8
128	Toll-like receptor 7 and 9 defects in common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2009, 124, 349-356.e3.	2.9	97
129	The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: Do they imply new risk factors?. Drug News and Perspectives, 2009, 22, 543.	1.5	11
130	The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: Do they imply new risk factors?. Drug News and Perspectives, 2009, 22, 543.	1.5	25
131	Memory B cells in common variable immunodeficiency: Clinical associations and sex differences. Clinical Immunology, 2008, 128, 314-321.	3.2	129
132	Expansion of regulatory CD8+ T-lymphocytes and fall of activated CD8+ T-lymphocytes after iv methyl-prednisolone for multiple sclerosis relapse. Journal of Neuroimmunology, 2008, 204, 131-135.	2.3	20
133	Eczematous Dermatitis in the Setting of Hyper-IgE Syndrome Successfully Treated With Omalizumab. Archives of Dermatology, 2008, 144, 1662-3.	1.4	34
134	Isolated type 5 antimitochondrial autoantibodies are associated with a history of thrombocytopenia and fetal loss. Fertility and Sterility, 2007, 87, 976.e17-976.e18.	1.0	5
135	Conferencia clinicopatolÃ³gica de la SEMI. Revista Clinica Espanola, 2007, 207, 36-44.	0.6	1
136	Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsingâ"remitting multiple sclerosis. Journal of Neuroimmunology, 2007, 182, 204-211.	2.3	114
137	Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: Differential short-term changes on corticosteroids therapy. Journal of Neuroimmunology, 2006, 176, 153-161.	2.3	53
138	Association of antiâ€"cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 55, 657-661.	6.7	22
139	Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 562-563.	1.9	38
140	Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus, 2006, 15, 881-885.	1.6	45
141	Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis. Journal of Rheumatology, 2006, 33, 1476-81.	2.0	15
142	Pregnancy-induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity. Immunology Letters, 2005, 96, 195-201.	2.5	74
143	Prevalence of IgG Anti-Î±-Fodrin Antibodies in SjÃ¶gren's Syndrome. Annals of the New York Academy of Sciences, 2005, 1050, 210-216.	3.8	18
144	Partial Response to Anti-CD20 Monoclonal Antibody Treatment of Severe Immune Thrombocytopenic Purpura in a Patient with Common Variable Immunodeficiency. Annals of the New York Academy of Sciences, 2005, 1051, 666-671.	3.8	35

#	Article	IF	Citations
145	HIV-1 Infection of Neurons Might Account for Progressive HIV-1-Associated Encephalopathy in Children. Journal of Molecular Neuroscience, 2005, 27, 079-090.	2.3	42
146	Discoid lupus erythematosus involving the eyelids. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 138-139.	2.4	13
147	Discordance between anti-beta2-glycoprotein-I and anti-cardiolipin antibodies in patients with clinical criteria of antiphospholipid syndrome. Clinical and Experimental Rheumatology, 2005, 23, 525-8.	0.8	5
148	Long-term asymptomatic Wallerian degeneration in patients with relapsing remitting multiple sclerosis: MRI and SPECT findings. European Journal of Radiology Extra, 2004, 52, 51-58.	0.1	2
149	Short-term sequential analysis of sex hormones and helper T cells type 1 (Th1) and helper T cells type 2 (Th2) cytokines during and after multiple sclerosis relapse. European Cytokine Network, 2004, 15, 197-202.	2.0	5
150	Palmoplantar pustulosis: a clinicoepidemiological study. The relationship between tobacco use and thyroid function. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 276-279.	2.4	57
151	Red fingers syndrome and recurrent panniculitis in a patient with chronic hepatitis C. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 692-694.	2.4	7
152	Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. Clinical and Experimental Immunology, 2003, 131, 130-137.	2.6	5
153	Neuroprotective effects of early antiretrovirals in vertical HIV infection. Pediatric Neurology, 2003, 29, 218-221.	2.1	32
154	Low Blood CD8+ T-Lymphocytes and High Circulating Monocytes Are Predictors of HIV-1-Associated Progressive Encephalopathy in Children. Pediatrics, 2003, 111, e168-e175.	2.1	56
155	ReconstituciÃ³n clÃnica e inmunolÃ³gica completa tras el tratamiento antirretroviral de gran actividad en un niÃ±o infectado verticalmente por el virus de la inmunodeficiencia humana tipo 1 con enfermedad avanzada. Medicina ClÃnica, 2003, 120, 417-420.	0.6	1
156	CD8+ T-Cell Numbers Predict the Response to Antiviral Therapy in HIV-1-Infected Children. Pediatric Research, 2003, 53, 309-312.	2.3	7
157	CD8+ T-Cell Numbers Predict the Response to Antiviral Therapy in HIV-1-Infected Children. Pediatric Research, 2003, 53, 309-312.	2.3	6
158	Characterizing Immune Reconstitution after Long-Term Highly Active Antiretroviral Therapy in Pediatric AIDS. AIDS Research and Human Retroviruses, 2002, 18, 1395-1406.	1.1	32
159	Impact of antiretroviral protocols on dynamics of AIDS progression markers. Archives of Disease in Childhood, 2002, 86, 119-124.	1.9	19
160	Immunological recovery after 3 yearsâ€™ antiretroviral therapy in HIV-1-infected children. Aids, 2002, 16, 483-486.	2.2	21
161	Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis. European Cytokine Network, 2002, 13, 110-4.	2.0	32
162	Reconstructing the course of HIV-1-associated progressive encephalopathy in children. Medical Science Monitor, 2002, 8, RA249-52.	1.1	5

#	Article	IF	Citations
163	Where does free infective HIV-1 rebound come from?. Aids, 2001, 15, 657.	2.2	2
164	ANTIPHOSPHOLIPID ANTIBODIES AND RETINAL THROMBOSIS IN PATIENTS WITHOUT RISK FACTORS. Evidence-Based Eye Care, 2000, 1, 160-161.	0.2	1
165	Polydactyly in 22q11 syndrome: should it be taken into account?. Clinical Genetics, 2000, 58, 84-85.	2.0	2
166	Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. American Journal of Ophthalmology, 2000, 130, 538.	3.3	9
167	Clinical Relevance of Cytokine Production in HIVâ€1 Infection in Children on Antiretroviral Therapy. Scandinavian Journal of Immunology, 2000, 52, 634-640.	2.7	0
168	Clinical Relevance of Cytokine Production in HIV-1 Infection in Children on Antiretroviral Therapy. Scandinavian Journal of Immunology, 2000, 52, 634-640.	2.7	11
169	Predictive Markers of Clinical Outcome in Vertically HIV-1â€“Infected Infants. A Prospective Longitudinal Study. Pediatric Research, 2000, 47, 509-515.	2.3	51
170	Correlation of Viral Load and CD8 T-Lymphocytes with Development of Neurological Manifestations in Vertically HIV-1-Infected Infants. A Prospective Longitudinal Study. Neuropediatrics, 1999, 30, 197-204.	0.6	20
171	Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus, 1999, 8, 274-278.	1.6	43
172	Adenoidal tissue mass as a clinical guide of disease evolution in vertically HIV-1 infected children. International Journal of Pediatric Otorhinolaryngology, 1999, 51, 145-155.	1.0	5
173	Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. American Journal of Ophthalmology, 1999, 128, 725-732.	3.3	93
174	Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases. Frontiers in Immunology, 0, 13, .	4.8	20